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The central dogma of biology dictates that sequence information encoded in DNA is transferred via
transcription to RNA and through translation encodes a protein. While this provides one level of control,
the majority of DNA, RNA and proteins are fine-tuned through chemical modifications that modulate their
structure and function. Proteomics by liquid chromatography/mass spectrometry (LC-MS/MS) is an
unbiased view into the world of these modifications by providing a tool to uncover their regulation and
function. Specifically, the study of RNA modifications has exploded due to the parallel advancement of
next generation sequencing and LC-MS/MS, but these technologies are incomplete due to the inability to
capture the full depth of RNA modifications in robust manner. In this work, we designed new methods for
the study of RNA modifications by creating a platform focused solely on improving the RNA MS.
Separately, we have applied new methods in LC-MS/MS to virus biology to uncover how post-translational
modifications (PTMs) of proteins govern RNA-protein interactions (RPIs). To this end, we investigated
how PTMs are globally affected by adenovirus infection and uncovered key PTMs required for viral protein
function. We identified a striking loss of arginine methylation due to the shuttling of protein arginine
methyl transferase 1 (PRMT1) into the cytoplasm, away from nuclear RBPs. Overall, both works provide
advances in mass spectrometry methods and illustrate their application, providing the tools to ask deeper
questions about RNA and protein modifications and viral biology.
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ABSTRACT

Richard Lauman
Benjamin A. Garcia

The central dogma of biology dictates that sequence information encoded in DNA
is transferred via transcription to RNA and through translation encodes a protein.
While this provides one level of control, the majority of DNA, RNA and proteins are
fine-tuned through chemical modifications that modulate their structure and function.
Proteomics by liquid chromatography/mass spectrometry (LC-MS/MS) is an unbiased
view into the world of these modifications by providing a tool to uncover their
regulation and function. Specifically, the study of RNA modifications has exploded due to
the parallel advancement of next generation sequencing and LC-MS/MS, but these
technologies are incomplete due to the inability to capture the full depth of RNA
modifications in robust manner. In this work, we designed new methods for the study
of RNA modifications by creating a platform focused solely on improving the RNA
MS. Separately, we have applied new methods in LC-MS/MS to virus biology to
uncover how post-translational modifications (PTMs) of proteins govern RNA-protein
interactions (RPIs). To this end, we investigated how PTMs are globally affected by
adenovirus infection and uncovered key PTMs required for viral protein function. We
identified a striking loss of arginine methylation due to the shuttling of protein arginine
methyl transferase 1 (PRMT1) into the cytoplasm, away from nuclear RBPs. Overall,
both works provide advances in mass spectrometry methods and illustrate their
application, providing the tools to ask deeper questions about RNA and protein
modifications and viral biology.
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The central dogma of biology describes DNA as being the blueprint for RNA and
eventually the translation of proteins. While this accurately represents much of the function
of nucleic acids, RNA can have several other distinct functions ranging from translation
inhibition to the editing of their own transcripts through self-splicing mechanisms. In
addition to this deviation from the central dogma, the canonical RNA moieties adenosine,
guanosine, cytidine, and uridine were first recognized as incomplete with the discovery of
pseudouridine in 1956, long considered to be the fifth base of RNA (1–3). This 5-base
paradigm persisted for decades despite the discovery of additional modifications before
the end of the 1950s (4). Mass spectrometry (MS) was first applied to nucleic acids by
McCloskey and Biemann in 1962, when they began studying multiple tRNA modification
simultaneously (5). This would eventually lead to the understanding of the structural
importance of tRNA modifications; however, this was considered the only role of these
modifications for many years. This perspective, along with technological limitations, led to
stagnation of biologically relevant work in the field until the discovery of m6A in mRNA led
to an RNA modification renaissance. m6A was shown to be critical in multiple cellular
processes across species, and it is necessary for life in many eukaryotes (6,7). Recently,
m6A has been shown to be required for proper splicing and is inducible in various
conditions to generate the correct spliceoform of certain proteins (8). The resurgence of
interest in RNA modifications led to additional discoveries of functional importance,

including RNA processing mechanisms, tRNA structure and stability, translation
machinery assembly through the m7G 5’ mRNA cap, and translation fidelity, among others
(9). Most recently, additional modifications have been found internally in mRNA, including
m6Am, m1A, and m5C. These discoveries clearly demonstrate that more mRNA
modifications could be unseen at low abundances, and the function of many of these
modifications have not been characterized. Additionally, interest has returned to tRNA
modifications due to clinical disorders associated with mutations in tRNA genes and/or
their modifying proteins, variable wobble position modifications, and inducible changes in
modifications (10). This has led to the targeting of the writers and erasers of RNA
modifications for clinical therapies, as the rapidly expanding knowledge of these pathways
has revealed high therapeutic potential (9,10). As such, the discovery of novel RNA
modifications and the expansion of methods to identify them is paramount to enabling
these translational studies.
The advancement of epitranscriptomics remains full of challenges, and mass
spectrometry is one of the most powerful tools in overcoming them. MS is a high-resolution
technique that has long been considered the gold standard for protein identification and
quantitation. The technology has been applied to nucleic acids with less prominence, but
it has proven critical, if not necessary, to the broad analysis of nucleosides, nucleotides,
oligonucleotides, and RNA interacting proteins. Indeed, MS is the most effective technique
at identifying previously undiscovered nucleic acid modifications and remains
unsurpassed in detecting proteins interacting with an immobilized oligonucleotide. These
factors demonstrate the unique application of mass spectrometry to epitranscriptomics. In
this section, we discuss the past, present, and future of MS techniques and technologies

that interrogate RNA modification abundance, localization, structure, function, and
interaction.
The biological impact of RNA modifications is most strongly related to the type of
RNA bearing the mark. Modifications of mRNA, especially m6A, have been most
extensively studied since the advent of modification sequencing (9,11). Modifications are
much less common in mRNA than other RNA types, and due to their low stoichiometry,
understanding their functions without localization was unsurmountable. Although
sequencing technologies yielded a surge in excitement and investigation into the effects
of these modifications, many of their functions remain enigmatic. Still, broad associations
have been drawn for some of the modifications in mRNA, which include m7G, inosine,
pseudouridine, m5C, m6A, and ac4C (Figure 1). For example, one of the best understood
RNA modifications is m7G, specifically in its function as the 5’ cap, which is used to identify
cellular RNA for cap dependent translation (12). Unlike polyA tails that are often used to
pulldown mRNA, the m7G cap is present in all translatable mRNA (13). Additionally, the
well-studied m6A modification has been implicated in structure, splicing, viral response.
Another modification, known for being deposited in DNA as well as RNA, is m5C. As it is
studied by bisulfite sequencing, it can be localized to sites of other cytidine modifications,
such as hm5C, m3C, and ac4C (14). The latter modification, ac4C, is a mark recently
discovered to be present in mammalian mRNA and, like other mRNA modifications, has
been shown to increase stability and translation fidelity (15). Previous studies using
bisulfite sequencing misidentified ac4C as m5C, highlighting the low accuracy of the
approach (16). Importantly, while mass spectrometry has not been able to analyze the full
profile of mRNA in a single run, it does not suffer from the same misidentification issues
as sequencing. Sequencing of m6A had similar issues in its infancy, with many of the hits

being false positives (17,18). As the field has grown, the technology has improved
dramatically and the technological limitations have been addressed (19–21). For example,
m6A identifications were not always noted as bases that could also contain other
modifications, such as m6Am (22,23). In fact, m6Am recently has been identified to mark
alternative transcription start sites without altering translation (24).
Essential to the identification of RNA modifications is the study of their epigenetic
relationships with the reader, writer and eraser proteins that regulate them. Recent
discoveries with m6A sequencing have shown direct splicing regulation of heterogenous
nuclear ribonucleoproteins (HNRNPs) and serine/arginine rich splicing factors (SRSFs)
interacting with this modification (25–28). These examples illustrate the focused research
on a few modifications to understand their context within RNA biology. As seen in Figure
3., there is limited knowledge of the modifiers and readers of common modifications, much
less all RNA modifications. One main goal is to expand the knowledge not only on the
epitranscriptomics, but to open the work to identify the proteins involved with all RNA
biogenesis and regulation.
While nucleosides and nucleotides can provide rich information of the fundamental
pieces of RNA, the context of these modifications within the transcript is lost. Method
design is currently underway to identify key interactors of RNA modifications and
understand the role RNA modifications in biological processes. Current NGS methods are
limited to single modifications per sequencing technique and multiple modification
sequencing results must be overlaid to expand coverage, increasing the possibility of
experimental bias. The use of LC-MS/MS allows for an unbiased approach to the
sequencing of RNA oligomers and can identify any number of modifications, given that
specific criteria are met. While the information generated by LC-MS/MS RNA sequencing

is rich, the difficulties surrounding the retention, fragmentation, and sequencing can be
quite difficult to the novice. Depth of coverage is an issue for any MS method and with
RNA consisting mainly of rRNA (80%) followed by tRNA (15%) and mRNA (5%) can be a
challenge to identify a single RNA species without resorting to enrichment strategies (29).
Even with enrichment, extremely diverse samples are plagued by isomeric coelution which
limits the throughput for longer RNA sequences. Still, the information gained
contextualizes much of the sequence and modifications within the identified RNA and is
beginning to grow into a well-established field of its own.
While much of the initial extraction is similar for NGS, the two workflows diverge at
the point of sample prep for their respective instruments. Many MS workflows are limited
to less than 100 bases due to the difficulty of ionizing large biomolecules, which is
compounded by lengths of many RNAs ranging from 20 bases to kilobases, in the case
of microRNAs and lncRNAs respectively (30,31). As well, LC-MS/MS requires careful
thought to the sample preparation and purity to ensure limited salts or contaminants are
present. Even further compounding the difficultly is the complicated fragmentation to
suitably sequence RNA fragments, which at first glance, appear to be a myriad of different
partial fragments. In this section, I discuss the experimental design for RNA mass
spectrometry analysis and critical steps for proper technique.
Cleaving the RNA reproducibly into suitable sizes for MS is the first step. Most
commonly used for enzymatic cleavage of RNA is the endonuclease is RNAse T1, which
targets specifically guanines, followed by RNase A, which cleaves primarily at pyrimidines
(32,33). Due to the lack of complexity in some RNA sequences, the Limbach group
designed a new endonuclease to nonspecifically target RNA and act akin to pepsin for
peptides (34). The choice of nuclease is highly dependent on the region of interest. Over-

digestion leads to loss of the region of interest while under-digestion results in oligomers
that are too large to enter the gas phase or properly sequence. For example, if the region
of interest includes a CpG-rich sequence, it would be advisable not use RNase T1 which
will over digest the transcript. After the proper size has been achieved, the next step is
ionizing the analyte of interest.
The common methods for ionizing RNA oligos are matrix assisted laser desorption
ionization (MALDI) and electrospray ionization (ESI), the latter of which can be coupled
with direct injection or liquid chromatography. MALDI is performed by laser irradiation of
a dry sample on a plate and is high throughput due to the rapid analysis of each sample.
However, the caveat for this method is the inability to analyze complex mixtures of species
(35). Ionization by MALDI provides easier gas phase entry for oligonucleotides by inducing
very soft ionization in a stable matrix (36,37). MALDI sources are commonly paired with
TOF (Time of Flight) analyzers, which generate the high-resolution mass accuracy data
necessary for identifying oligonucleotides (38). Oligo sequencing by MALDI-TOF has
decreased in use due to challenges in simultaneous analysis of multiple oligos and lack
of fragmentation. However, ESI LC-MS/MS or direct infusion is still routinely performed
today (33,39,40). ESI is used for RNA sequencing due to its compatibility with
chromatographic separation, despite the low sensitivity of negative mode MS and the
relative fragility of phosphodiester bonds (41–44). Chromatography poses an even greater
challenge as oligoribonucleotides do not bind to C18 columns without ion pairing reagents
(45). Ion pairing reagents act as a bridge between the negative charges of the phosphate
backbone and the hydrophobic alkanes of the C18 resin (46,47). During ionization, ion
pairing reagents disassociate from the analyte, but can lead to ion suppression, ion burn,
and other difficulties with MS as they begin to accumulate (48,49). The Limbach lab

recently illustrated the use of HILIC (Hydrophilic Interaction Chromatography) without ion
pairing to retain and release synthetic oligos, a method that could be applied to a wider
range of samples (45). Since RNA itself is sensitive to basic or extremely low pH: it is
crucial to not use extreme mobile phase buffers for the binding of RNA without on column
hydrolysis or fragmentation (50). Due to these complications, it is advised for larger
sequences to simply remove liquid chromatography completely and move to direct
infusion (51–53). This removes many of the previously mentioned complications, but with
the caveat of limiting the complexity without some means of separation. One means of
circumventing this issue is the use of ion mobility to separate analytes, creating some
separation by size, charge and base content and allowing for more robust analysis of each
fragment (51,54,55). With the RNA of interest properly retained, ionized, and contained
within the gas phase the next step is to then identify the analyte by fragmentation.
Fragmentation in any MS/MS workflow is the standard means of fingerprinting and
identifying the analyte of interest, and RNA is no exception. Fragmentation of the RNA
oligo as seen in Figure 4 consists of cleavage along the phosphate backbone (a/w, b/x,
c/y, d/z ions), fragmentation at the glycosidic bond (base/a-base or m-base), and the loss
of a single phosphate, all of which are useful for analysis (56,57). Common ribonucleotide
fragmentation techniques consist of previously described “beam type” fragmentation such
as higher order c-trap dissociation (HCD) and trapped fragmentation techniques such as
collision induced dissociation (CID). Fragmentation using HCD/CID creates primarily w/mB, c/y and w/a ions (Figure 4 for reference), assuming a properly tuned fragmentation
energy (58). Even normalized HCD fragmentation energies can be difficult to properly tune
for highly charged oligos. Depicted in Figure 5 is the effect of normalized fragmentation
with increasing length of oligos and charge, illustrating the need to control charge and

length during fragmentation. As with peptides, electron transfer can fragment negatively
charged RNA, described as electron donation dissociation (EDD). Alternatively, lightbased fragmentation such ultraviolet photodissociation (UVPD) and infrared multiphoton
dissociation (IRMPD) can be used for charged, longer oligos (56,59,60). These two less
prevalent fragmentation types have shown parity in fragmentation sites for RNA oligos,
creating the possibility of focused fragmentation to a particular bond or region of interest.
EDD fragments along the phosphate backbone of the oligo creating w/d and a/z ions and
in the order of bases by G>U/T>A>C, while EPD fragments in the order of G>A>C>U/T
utilizing differing forms of excitation to break the bonds (61,62).

Radical based

fragmentation techniques for positively charged species of DNA such as ECD (Electron
Capture Dissociation) and ETD (Electron Transfer Dissociation) have been used primary
for DNA and been adapted for RNA, but are limited due to the acidic nature of the RNA
where neutral losses would be abundant (59,63–65). Beyond these are the combination
of the aforementioned hybrid activation techniques such as ET-IRMPD and ET-UVPD.
These techniques retain the modification, resulting in better sequence coverage due to
greater distribution of fragments and enabling improved site localization (66). The
fragmentation types CID/HCD are best for smaller oligonucleotides that range between
10-20 bases and are compatible with radical or photon-based fragmentation, but the major
issue of charge state limits in fragmentation remains. Oligonucleotide charge control is
paramount for proper fragmentation, with charge states of -4 to -9 being the most common
charge states for 20mers. Looking beyond current techniques of fragmentation, we believe
the advent of new technologies will allow for more complex and better fragmentation of
longer RNA.

Due to the inherently complex spectra, sequencing an RNA of interest can be
difficult to master. As depicted in Figure 4, the fragmentation points are numerous, with
four different positions to fragment around the phosphate and base loss. This can lead to
troublesome mapping of RNA, as many fragments may have isobaric species or
convoluted spectra, rendering the localization of the modification difficult. For instance, a
methyl mass shift may be a 2’-o-methyl mark or a methyl base, illustrating the need for
rich spectra and diverse fragments. An example is illustrated in Fig. 6 where the
modification is not present on the base (as seen where there is no mass shift) and the 2’o-methyl mark can be observed. An additional example lies in the uridine isomer pseudouracil lacking a labile glyosidic bond, which allows for the identification of the base and
sugar but not base alone (67). To localize a base methylation however, the method must
include a higher energy targeted MS3 to properly identify each isobaric base modification,
as referenced previously in this manuscript. Manually scoring spectra is quite difficult
without the use of new sequencing software, especially with at least 150 individual
modified and isobaric modifications on only 4 bases.
With the rise of newly discovered RNA modifications, it has become paramount to
design new sequencing software to localize modifications on RNA transcripts. Since the
mid 2000’s, sequencing algorithms for RNA mass spectra have been introduced and as a
result, the number of RNA modifications has significantly grown (68,69). More recently,
the Limbach and Isobe groups have combined modified RNA sequencing by MS to
provide an alternative and comprehensive analysis of RNA modifications using new
software akin to the proteomic sequencing software (70–73). As the field continues to
grow, we need to rectify differences in RNA-seq statistical analyses and those commonly
performed by proteomics workflows to better improve the overlap of the two fields (74,75).

Modifications on RNA can modulate interactions between the RNA and reader
proteins, acting as a functional switch for RNA secondary structure and/or protein binding
(64). Protein and RNA interactions also change the epitranscriptomic landscape by
modulating the expression of specific transcripts. Examples of this being targeted mRNA
degradation mediated by Argonaut 2/RISC complex and inhibition of the histone
methyltransferase activity of the

repressive complex (PRC2) complex due to

RNA binding (77,78). While RNA/protein interaction sites can be mapped through different
biochemical assays, they lack the coverage and high throughput analysis offered by LCMS/MS methods.
Identifying specific RNA binding proteins by biochemical means can be difficult due
to the required prior knowledge of the proteins involved. To specifically identify the proteins
bound to and interacting with RNA, a trapping method must be performed to ensure the
interaction is direct. Photoactivatable crosslinking by RNA analogs such as 4-thioluracil
(s4U), 6-thioguanosine (s6G) (both crosslinked at 365nm) and native uracil (crosslinked at
254nm) covalently link the RNA interacting proteins to the RNA, dramatically increasing
specificity (79). Photoactivatable RNA crosslinking immunoprecipitation (PARCLIP) based
methods crosslink RNA to protein in live cells through a radical formation on the base,
which is considered a zero-length crosslinker due to the tight distance constraints (79,80).
RNA antisense probe mass spectrometry (RAP-MS) enriches a target RNA using an
immobilized antisense probe and pulls down the RNA binding proteins (RBPs) specific to
the target RNA, though complications in identifying specific binding RBPs can be due to
the promiscuous nature of their interactions (81–84). Stable isotope labeling of amino

acids in cell culture (SILAC) can improve the quantitation of RAP based approaches by
directly comparing the RNA binding proteins for a known RNA sequence to those captured
by a scramble RNA probe (85). While RAP MS is a straightforward approach for identifying
direct interactors of RNA by MS, it does not provide us with the RNA binding regions of
the proteins.
Once the proteins that interact with a specific RNA are identified, the next step is
to uncover the proteins’ RNA binding motif. There are several different approaches used
to identify RNA binding regions, but they employ one of two different forms of proteomics:
positive identification (ID) or negative ID (Figure 7). Positive ID localizes the site of
nucleotide crosslinking on the peptide by a searching for a predicted variable mass shift
in the protein sequence. This approach, two methods named RNA-Protein crosslinking
(RNPxl) or RNA Binding Site ID (RBS-ID), takes advantage of phosphate group enrichment
for nucleotides and pinpoints crosslinked RNA to the peptide though a software analysis
(86,87). The use of this technique is limited by the low number of identified crosslinked
peptides due to the fragile nature of the nucleotide, the difficultly of achieving full
crosslinking, and complications with sequencing analysis. In contrast, negative ID of RNA
interaction sites uses the missing peptide to map the RNA interacting region of a protein.
In this approach, RNA binding domain map (RBDMap) and peptide crosslinking affinity
purification (pCLAP) identify RNA binding sites through sequential digestion of crosslinked
RBPs (88,89). A specific protease (LysC/ArgC) is used first to cut at lysine or arginine,
followed by a protease with low specificity (trypsin) to generate peptides adjacent to the
crosslink site. The RBDMap technique was improved upon with the orthogonal phase
separation to remove uncrosslinked protein and RNA (XRNAX or OOPS) (90,91). The
dropout peptide adjacent to the peptides identified is then scored and mapped to a

structure of the protein. Another technique focusing on the use of negative ID is RNA
binding region identification (RBRID), a nonspecific approach to RNA interaction discovery
that identifies dropouts of specific peptides by comparing them a non-crosslinked control
(92). Although simple in application, the negative ID method is prone to false positives and
thus requires validation through an alternative positive ID technique. Indeed, the methods
described above are able to uncover proteome-wide RNA and protein interactions, but
each lacks the specificity and coverage of single protein work.
The previously mentioned RNA interaction mapping techniques can be combined
with hydrogen deuterium exchange (HDX) to deliver a more comprehensive map of RNAprotein interactions at the amino acid resolution. HDX depends on the relative solvent
exposure of different regions of proteins to identify the sites of interaction (93). Thus,
protein-bound RNAs will cause a decrease in solvent exposure of the protein at the site of
interaction, uncovering the specific RNA binding site (94,95). Although proteins are the
typical subjects in HDX studies, RNA-protein complexes rarely analyzed due to the
complex nature of phase separation (96,97). RNA and/or protein aggregation and phase
separation can be difficult to avoid due to the high concentrations of RNA and protein
required for HDX (98). Despite these challenges, HDX can pinpoint the RNA interaction
sites of proteins to an amino acid resolution. High resolution mapping of protein
conformation shifts with the presence of RNA have been shown for the Enhancer of zeste
homologue 2 (EZH2) member of PRC2, viral capsid proteins, and viral RNA interacting
proteins (99–101). Although this technique is not commonly used for RPIs, HDX can shed
light on the structural changes induced by protein-protein interactions and their posttranslational modifications, an approach underutilized in understanding the function of
these modifications.

Different RNA and protein interaction mapping methods have been designed for a
multitude of studies. Each of the methods discussed, combined with RNA MS sequencing,
will generate a wealth of information for the epitranscriptomics field. Mapping interactions
and structural changes of proteins when bound to modified RNA provides clues for the
function of each modification. Currently, there is a substantial lack of knowledge of the
readers, writers, and erasers of modified RNA. The future of MS will fill these gaps, as MS
is the only modern technology capable of simultaneous sequencing of the peptide and
associated oligo in a crosslinked molecule. Proteins and RNA play critical roles in the
epitranscriptome, and using and improving the techniques available will paint a greater
picture of its landscape.

Since the 1950s Adenovirus has generated a wealth of knowledge from the
discovery of alternatively splicing, DDR pathways and gene therapies. Adenovirus is a
double stranded, 36 kilobase (kB) DNA virus forming an icosahedral capsid (102). During
infection the capsid enters the host cell via binding of the CAR (Cocksakie and Adenovirus
Receptor) and endocytosis. In the cytoplasm, the capsid evades viral DNA sensors such
as cGAS/STING to deliver the viral genome to the nucleus (111,112). Once within the
nucleus, the virus coats itself with cellular proteins to avoid detection by the host immune
system and begins expression of early-stage viral proteins (104,105). These early proteins
block host sensing and limit apoptosis pathways though the binding or degradation of host
proteins (106,107). The virus replicates by hijacking host machinery and simultaneously
recruiting host proteins to splice viral transcripts to translate more complex species known
as late proteins. Late proteins have known functions to facilitate the viral takeover of host
transcription and translation, then finally to guide and construct viral progeny (108).

Adenovirus has created an elegant system to slip into cells undetected, supplant cellular
machinery away from cellular transcripts and lyse cells to release their viral progeny. An
old adage goes that “viruses make better biologists than scientists do” given their
specialized abilities, and adenovirus is no exception.
To infiltrate any cell, all viruses must reduce or deactivate any host sensors or
pathways deleterious to the viral replication cycle. Unsurprisingly, DNA viruses are
susceptible to the host cell’s DNA Damage Response (DDR) pathway which can resect
the viral DNA into the host genome and stop viral infection (109). To evade and limit the
host response, adenovirus manipulates host factors to degrade cellular protein sensors,
removing host control over host systems. The degradation is primarily accomplished by
viral proteins E1B-55K and E4ORF6 usurping the host ubiquitin E3 ligase complex to
degrade interfering host proteins (109). Viral E4ORF6 acts as a scaffold between the E3
ligase and E1B-55K, which recognizes the substrates for deposition of ubiquitin (110,111).
To ensure that the DDR pathway is not activated, the virus targets the MRN (MRE11,
RAD50, NBS1) complex for degradation using E4ORF6/E1B-55K and is also relocalized
away from viral replication centers by E4ORF3 as an added measure (112). Adenovirus
protein VII also protects the viral genome by sequestering host proteins HMGB1 and SET,
a modifier of DDR proteins (104). Thus, by employing alternate and redundant pathways,
the virus ensures infection continues with no limit by host defenses.
In 1977 the labs of Rich Roberts and Phil Sharp made the startling discovery that
RNA transcripts of adenovirus virus were discontinuous regions of the viral genome
(113,114). They had in fact identified alternatively spliced viral transcripts. In the late
phase of adenovirus infection, the Major Late Transcription Unit (MLTU) splits into a
myriad of transcripts, each encoding a different late viral protein (115). Given that the

adenovirus genome is only ~36 kB, alternative splicing not only plays a crucial role in
expanding the number of proteins available, but also allows temporal regulation of mRNA
transcripts. Recent work using Nanopore long read sequencing identified a large number
of previously unidentified viral fusion protein transcripts and isoforms, illustrating an even
greater variety of proteins during infection (116). Viruses are masters of utilizing the bare
minimum in genome to efficiently take over the cell.
During adenovirus infection the virus changes roles throughout the course of
infection as the cell is made more hospitable for infection. As described above, early onset
viral proteins infiltrate the host cell to remove sensors that could inhibit viral replication,
followed by late onset proteins that promote viral packaging and progeny production. To
achieve this, the adenovirus transcriptome must “switch” from an early phase program to
late phase, defined by the preferential expression of late protein transcripts. Classically,
transcripts are distinguished by the temporal nature of their expression relative to DNA
replication, such as early (E1A, E1B, E2, E3, E4) and intermediate (IVa2, pIX and L4)
transcripts. Late transcripts are derived from the MLTU and are divided into 5 different
classes (L1-L5) based on polyadenylation sites (117,118). These transcripts translate into
proteins with essential functions for each stage of infection, with DNA binding protein
(DBP) expression being a marker of the transition from early to late phase. While the
MLTU is expressed throughout infection, it is only expressed from the L1-52/55k region to
a splice site at IIIa repressor element (3RE), and is mediated by serine/arginine-rich
splicing factors (SRSFs) (119–121). Once sufficient early protein E4ORF4 is expressed,
it binds to SRSF1 directly and recruits PP2A to dephosphorylate SRSF1: releasing SRSF1
from the 3RE element and allowing for alternative splicing (122,123). This mechanism is
hypothesized to be one of many possible regulators of the diverse, late phase viral

transcripts that originate from MLTU. Importantly, these transcripts encode proteins that
usurp the disinhibited host proteins to facilitate adenovirus RNA splicing (124,125).
Beyond the manipulation of SRSF proteins, the virus also controls other host
proteins to remove their repressive effect on viral splicing. As described previously,
adenovirus uses the ubiquitin E3 ligase complex to recruit and degrade DDR proteins
early in infection. However, not all host proteins ubiquitinated by the virus are degraded;
some remain and are modulated in function. In particular, hnRNPC is found to be removed
from viral splicing late in infection by the addition of non-degradative ubiquitin (126). Upon
closer inspection, the addition of ubiquitin modulates the RNA and protein interaction
profile within the RRM indirectly, thus altering protein function without locally changing the
hnRNPC RNA binding motif. Crucial splicing proteins, such as hnRNPs and SRSFs, can
be temporally regulated by PTMs for the convenience of viral infection, but the extent of
this manipulation for the benefit of adenovirus infection is currently unknown.
Viruses are master manipulators of host cell regulation with RNA and protein
interactions being no different. Highlighted in the previous portion of this section,
adenovirus utilizes PP2A and the E3 ubiquitin ligases to manipulate SRSF1 and hnRNPC
respectively, but the study of adenovirus manipulation of host RBPs has been limited to
only a few proteins overall. To map the sites of changing global RNA-protein interaction
and the changing PTM landscape during infection, we will overlap identifications of both
changing RNA-protein interactions and post translational modifications during infection.
Recent work to identify host and viral RNA binding proteins has been performed in RNA
viruses, but we have yet to identify changing regions of interaction during a DNA virus
infection. Viral proteins manipulating host PTMs can create a myriad of different paths to
study how specific PTM sites can regulate a RBPs ability to recognize, bind or regulate a

target transcript. Thus, the study of this work can open up a new field of interrogation of
the identification and regulation of RNA-protein interactions.

Figures

Figure 1. Functions of modifications found on mRNA, tRNA, and rRNA

Figure 2: Example numbering schemes for pyrimidines (uracil, top) and purines (guanosine, bottom)
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Figure 4: An example RNA oligonucleotide with possible fragmentation sites in blue and
possible modifications (mostly not co-occurrent) in red.
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Figure 5. Complications with oligonucleotide fragmentation by HCD with highly charged species. HCD fragmentation of two
human rRNA oligomers at 10% HCD. Sequence coverage by NASE algorithm.
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Figure 6. A)An example of mapping data RNA oligonucleotides to specific sites using HCD fragmentation. Using 10% nHCD
to fragment a small RNA oligomer with a 2'-o-methyl uracil modification using NASE software for support. B) The zoomed in
spectra identifying bases and the lack of the methyl uracil base indicating a 2'-o-methyl modification.
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Figure 7. Advantages (Black) and disadvantages of RNA-protein interaction by MS
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The majority of DNA, RNA and proteins are fine-tuned through chemical
modifications that modulate their structure and function. Proteomics by liquid
chromatography/mass spectrometry (LC-MS/MS) is an unbiased view into the world of
these modifications by providing a tool to uncover their regulation and function.
Specifically, the study of RNA modifications has exploded due to the parallel advancement
of next generation sequencing and LC-MS/MS, but these technologies are incomplete due
to the inability to capture the full depth of RNA modifications in robust manner. In this work,
we designed new methods for the study of RNA modifications by creating a platform
focused solely on improving the RNA MS. We have designed a new form of liquid
chromatography for RNA utilizing Electrochemically modulated liquid chromatography
(EMLC). We have also advanced the use of FAIMS instrumentation for an ultra-fast
method for studying RNA modifications. Combined these two methods create the promise
of a new platform for RNA MS and can open the doors to new discoveries.

Currently over 130 unique RNA modifications have been discovered and a select
few RNA modifications have been extensively studied, such as m6A and 2’-o-methyl (127).
Only a select few highly abundant RNA (rRNA and tRNA) modifications have been fully
mapped using a combination of RNA sequencing and mass spectrometry (MS) techniques
(36,128). MS is essential for RNA modification sequencing due to the capability to site
localize modifications at the transcript and base position level. While current sequencing
techniques are limited to antibody-based enrichment, MS can mitigate several of these

issues by simultaneously identifying a multitude of modifications and distinguish isobaric
species, however, there are several limitations which impose difficulties on performing
RNA MS. Due to the polar nature of the RNA phosphate backbone, RNA cannot be
retained on the commonly used C18 resin without the use of ion pairing reagents: reagents
which can suppress RNA ions and decrease the desired analyte’s signal (49). The
phosphate backbone of RNA is capable of carrying a charge in proportion to each of the
bases, creating a highly charged and long polymer. To address the limitation of limited
fragmentation due to charge, several advanced RNA fragmentation techniques (AI-NETD
and UVPD) are being incorporated into instruments to combat this issue (66,129). Overall,
there are still many limitations to overcome for RNA MS to become a common and reliable
form of RNA modification quantification.
While data dependent acquisition (DDA) can be all-encompassing in order to
identify and quantitate many different analytes, the method is limited in its ability to discern
isobaric species. While there are other forms of acquisition methods to remedy the
limitations of DDA, one technological means is with the use of ion mobility to separate out
isobaric or low-level enrichment analytes for MS (94,95). Recently, there has been a
resurgence of this technique given the deeper coverage of the proteome and the trapping
limitations of other high-resolution MS instruments. Ion mobility instrumentation branches
into two different groups: High-Field Asymmetric Waveform Ion Mobility Spectrometry
FAIMS) and drift tube ion mobility (132,133). In drift tube ion mobility, as the ion moves
through gas and is accelerated by a voltage, the ion is bombarded by moving gas particles
that separate ions by cross sectional area and charge (or the reverse in some instruments)
(130,134). For FAIMS based ion mobility, an asymmetric wave which is applied to each
ion species, and unlike drift tube ion mobility, selects only for a specific distribution of ion

cross-sectional area and charge (135). Exploratory work performed by the Fabris lab
utilized drift tube ion mobility to separate isobaric modified RNA nucleosides, illustrating
the application of ion mobility without the use of LC (136). The growth of ion mobility in all
MS fields has led to increased selectivity of a traditionally unbiased technique into new
applications of MS.
In this work we have designed two new methods for the analysis of RNA
ribooligonucleotides that include the identification and quantification of RNA modifications.
In the first method, we have created a new type of chromatography for RNA MS, blending
together the voltage with porous graphitic carbon (PGC). As a separate instrumentation
method design, we have utilized FAIMS to target and enrich RNA species for far better
fragmentation and confident modification site localization. Our goal with this work is to
expand the utility of RNA MS from a validation step to greater discovery. By first having
reproducible LC and suitable depth of coverage, we can begin to sequence far more
difficult RNA species with the eventual goal of sequencing the entire transcriptome and
expand our knowledge of RNA biology. This work will expand the current toolkit for those
studying RNA biology, and allow for faster acquisition and deeper coverage of RNA
modifications of interest.

Results
This work began, as many do, with a mistake followed by a discovery. Given RNA
does not bind to C18 silica resin, we attempted to bind and release RNA from porous
graphitic carbon (PGC) using increasing amounts of methanol and a polar discharge to
release accumulating ions. We chose to initially test our methods using human ribosomal
RNA (rRNA) digested with Mg II cation-based hydrolysis, which creates a randomized
fragmentation on the rRNA (137). Chemical fragmentation was key due to the poly G and
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poly U-rich sequences in rRNA where a typical RNase would over-digest creating too
small of RNA species. In our first attempt to sequence using fragmented rRNA, we were
unable to identify any RNA (highly charged negative species) until we fortuitously switched
from negative to positive mode on the instrument. To our surprise, RNA was released from
the column as visualized by the large RNA species at the singly charged state in positive
mode. This led to the hypothesis that the voltage potential adjusted the solid phase PGC
to either bind or release RNA oligonucleotides depending on the direction of the potential.
To further study this RNA interacting phenomenon, we designed a simple trap
column with PGC to bind and release RNA selectively with a crude manual voltage switch
on column. This involved two alligator clips placed on either side of the column and a
power supply attached to a fritted and PGC packed 75-micron trap column. Wire leads
were attached to either end of the PGC column to conduct the electricity. To ensure the
minimal amount of voltage leaking or contamination from other sources, metal unions were
connected to silica lines and a grounding wire was placed between the source and the
column. The leads were placed in negative mode or “reverse mode” to act as the holding
agent for the RNA on the column during the loading sequence and start of the run. During
the middle of the acquisition run the leads were switched to release the RNA from the
PGC and then, in a data dependent acquisition (DDA) manner, sequence the RNA
fragments. Figure 1A depicts the RNA released from the column at the point of switching
voltages in the center of the run. Within the intensity heatmap, two distinct clusters of
masses are identified around 300m/z and 600m/z, within the relative range of the masses
of a nucleotide and dinucleotide respectively. Given that the charge of RNA is found on
the phosphates, the polymers of a given RNA nucleotide length repeating 300Da confirms
that these multiply charged species are RNA.

Following up on this initial finding, we tested the ability to selectively elute species
by our chromatography method by discerning a known “spike in” species of RNA using a
biotinylated D. melanogaster Let7a mature microRNA (Figure 1B). The microRNA spike
was identified in the complex mixture of mainly rRNA and the LOD (Limits of Detection)
were estimated to be 22 attomolar. With this initial work we had designed a new type of
RNA chromatography, but to further test our method we required more rigorous testing.
From these initial findings we theorized this RNA chromatography technique is
dependent on a blend of two different factors: hydrophilicity and pi stacking interactions.
Porous graphitic carbon is a sp2 structured carbon in a repeating stacked plane (138). The
ample amount of pi bonds within graphene allows for pi-stacking with the nucleotide base,
useful for retaining oligonucleotides to nanotubes and DNA sensors (139). While pi
stacking alone is a strong interaction force between the RNA and graphene, another
interaction guiding force is induced dipole interactions, resulting from the charge density
within graphite. As illustrated in the West et al. review, PGC contains a polarity difference
between the edge, middle and center of the planar graphite, and we theorize the electron
dense phosphate will interact with the delta-positive charge of graphene (138). This
interaction (and the manipulation by voltage) is further supported by Marc Porter’s work
on electrochemically modulated liquid chromatography (EMLC), which used the
conductive nature of PGC to retain and elute small molecules (140,141). Given these
qualities and previous analysis, graphite could act more akin to a zwitterionic resin to bind
both the positively charged base and negatively charged phosphate backbone. Indeed,
the binding of RNA to PGC can be quite strong depending on the length of the RNA and
in fact, further uncovered later in this work.
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Two major considerations for all LC-MS/MS work are the buffer conditions and
gradient design: with RNA MS is no different. The gradient itself was supplemented with
methanol to more efficiently elute RNA, but with the caveat of increasing backpressure
onto the column and clogging. While the nature of RNA interactions under high pressure
is unknown, the precipitation of RNA during extraction processes is performed with 70%
ethanol: indicating a high organic content of the mobile phase could precipitate RNA on
column. To mitigate this, we kept our elution percentage of mobile phase B always below
75% organic, which limited our precipitation and clogging issues. Beyond assisting in
elution, methanol is also ideal when performing assisted ionization necessary to ionize
larger RNA molecules efficiently. The methanol destabilizes the hydrogen bonds that form
between RNA and the solvent, further aiding in ionization. Using this principle, we decided
to create a linear hydrophobic gradient, commonly used in reverse phase LC-MS/MS, to
assist ionization of larger RNA at the end of the gradient. One critical element to consider
in addition to hydrophobicity and hydrogen bonding is pH. Typically, an LC-MS/MS buffer
is used to keep the charge of the analyte at a specific state, for example, in both
metabolomics or proteomics the addition of formic acid forces retention of the positive
charge for selection and fragmentation. For analytes which require negative charge, such
as small molecule acids or in this case RNA, increasing the pH will stabilize a negatively
charged species. For RNA, there is an additional consideration to not create a charge
state greater than -10 due to the limitations of conventional fragmentation. Limiting the
RNA charge state to -3 to -10 facilitates fragmentation pathways which are far more varied
and thus not requiring the use of higher charge state fragmentation methods such as AIETD (129).

Given RNA’s fragile nature in the gas phase, fragmentation becomes a difficult
obstacle to achieve without focused consideration. Importantly, one needs to allot
adequate fill time to accumulate ions for fragmentation due to the charge dependency of
HCD/CID for proper fragmentation. This step must be carefully considered when
identifying RNA species, particularly the site-specific localization of RNA modifications
which requires dense and rich spectra. We were initially limited by the RNA fragmentation
pathways due to the fragile nature of RNA in the gas phase. To overcome this, we
increased the Automatic Gain Control (AGC) target and extended out Maximum Inject
Time (MIT) to 300% and 200ms respectively. This change allowed for a drastic
improvement in the spectra generated and improved our site localization capabilities in
future runs. We can localize the location of the fragment at single base resolution and
distinguish a base modification or on the ribose - datapoints that are critical for assigning
the location of an RNA modification.
After optimizing the conditions to properly run RNA MS/MS, we focused our efforts
on testing the new method design against a known standard human rRNA. Human rRNA
is highly characterized at both the sequence and PTM level and is an ideal reference for
validating this method (142). We first sought to identify the ideal elution voltage with a
voltage ramp, validating each voltage’s ability to retain RNA from the PGC trap column
and determine if voltage elution was dependent on size or charge. A constant voltage was
applied to the column to change the binding affinity of RNA and elute with each voltage
using the same linear hydrophobic gradient. Increasing voltage created a different
distribution of MS2 acquisitions as the elution continued throughout the run, illustrating the
mobility of RNA with increasing voltages (Figure 2B). As expected, each peak of elution
starts near the initialized acquisition, but interestingly there was a large peak
which
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dominated the MS2 acquisition at the center of each gradient. More MS2 targets were
observed with higher voltages eluting after this initial peak, indicating more RNA targets
for fragmentation. Overall, we identified a dependence of RNA elution based on the
voltage applied as the initial start of our gradient redesign.
After identifying the relationship between voltage and elution, we next asked if RNA
length was correlated to a specific elution voltage. Each stepwise increase of voltage
contains a different distribution of RNA with a range of lengths (Figure 2C). With each
subsequent increase of voltage, we identified longer RNA species eluted by the increasing
voltage. Without any voltage applied RNA still eluted from the column, but at 5V we saw
a release of shorter RNA species at the beginning of the run. This curious response is
exemplified at 15V with the widest range of lengths eluted and from there a decrease in
length with increasing voltage. Thus, RNA length plays a major role in retention, with
increasing voltages releasing longer RNA species with diminishing elution at the 25V,
indicating that 30V is sufficient to release all RNA. Overall, we were able to design a
method able to specifically elute RNA in a stepwise manner and to encapsulate the
release of RNA in a sequential manner we designed a two-dimensional gradient.
To evenly elute all of the RNA species within a single run, much like proteomics,
we created a stepwise voltage gradient from 0-30V alongside a linear hydrophobic
gradient (Figure 2D). The increasing stepwise voltage gradient was chosen to “release”
the population of RNA evenly throughout the gradient and “wash” the trap column at the
end of each run. Distinct populations of RNA are eluted at each voltage step with fewer
larger RNA species eluting at the earlier retention times. Later in the run, however, longer
and higher charge state species appear. This distribution of charge and length illustrates
the mechanism for RNA release from PGC involves the charge state and length of the
2

species. RNA species of all sizes elute earlier from the column with a charge state greater
than -10, but at the later retention times the longer species appear lower charged.
Recalling the charge density of PGC, we can explain this release of the highest charge at
the highest voltage by the shifting positive charge of the graphite with the increased
voltage. From here we could further qualify our data and remap both the modifications and
coverage over rRNA.
After identifying the mechanism of RNA retention, we sought to establish the
coverage of both sequence and modifications of rRNA. With EMLC we can isolate specific
types of RNA and modified RNA from the elution within the same run, as seen in Figure
2E. Unsurprisingly, modifications elute throughout the LC-MS/MS acquisition without
parities to modification type, supporting the mechanism that the phosphate backbone
charge directs the voltage dependent interaction. The modifications identified cover the
wide majority of known modifications on rRNA as identified in Taoka et al. The sum of
quintuplicate LC-MS/MS acquisition generated over 1000 unique RNA sequences from
rRNA that were able to be mapped back to the human rRNA 80S ribosomal subunits at
about 70% with the non-unique sequencing covering >90% of the rRNA 80S ribosomal
subunits (Figure 2F). Unfortunately, due to the lack of sequence complexity of the rRNA
several of these sequences aligned nonspecifically throughout the 80S rRNA. These
ubiquitous non-unique species were highly charged and shorter species of RNA below the
minimum length to map to the sequence specifically. These higher charge state and
smaller sizes were due to limitations in our identification of fragments using the DDA
method design. While capable of sequencing a complex RNA species such as rRNA, a
major issue in RNA MS is the lack of selectivity of RNA species and moving forward we
sought to improve this limitation.

With our LC method fully designed we sought to improve the method by increasing
the selectivity and limits of detection of RNA by MS. To this end, we installed a Field
Asymmetric Ion mobility Mass Spectrometry (FAIMS) to the instrument to add a selection
component using ion mobility. FAIMS at this point in time had yet to be used in negative
mode and had never been previously used on long negatively charged biopolymers of any
kind. With this in mind, we used the biotinylated D. melanogaster Let7a RNA standard,
previously used to measure our EMLC, to test the use of FAIMS. To simplify our platform,
we used an Advion NanomateTM direct injection system to limit the difficulties surrounding
RNA LC work outlined previously. The Nanomate delivers a set injection of 1-5 microliters
at a flow rate of around 50 nanoliters per second to ensure a stable spray and a consistent
flow of ions to the MS.
Work by a previous graduate student Sam Wein revealed that salts from the RNA
purification process can damage the nozzle chips used to spray the analyte of interest
directly into the MS. We adapted our RNA preparation protocol to use a weak anion
exchange (WAX) stage tip protocol that was originally used for DNA using the
commercially available TopTipTM. While the addition of the WAX drastically improved the
removal of salts, it also needed to be done on ice and as quickly as possible to limit the
degradation of RNA by high pH hydrolysis. Despite this caveat, we were able to purify
RNA without major salt adducts and contaminants, improving ionization and quality of
signal.
The first test consisted of ramping through the compensation voltages to select for
the Let7a 22 nucleotide microRNA. To our surprise, we enriched Let7 with a charge state
(z) distribution starting at z=-15 and ending at z=-7 at the far end of the spectra window of
3000 m/z with a FAIMS CV value of 55 (Supplemental Figure 3.1). Using the selective

nature of FAIMS, Let7a was gas phase enriched over the background and contaminant
peaks with in spectra. In comparison to the early LOD EMLC experiments, we infused less
than 1nM actual concentration and separated a clean peak, which was astoundingly
selected over the noise far better than our previous method design. We then removed the
FAIMS instrumentation and then sprayed with the same conditions and could not identify
the RNA, even with adjusting the automatic gain control (AGC) and maximum inject time
(MIT) to account for decreased intensity species. Of note, the increased presence of singly
charged RNA nucleotides present without FAIMS, likely due, to the singly charged species
“competing” for the signal. This “signal competition” is due to the Thermo instrument CtrapTM accumulates a set number of charges determined by the AGC (143,144). Given
singly charged species contain one charge per ion rather than multiply charged species,
singly charged species will limit the diversity of ions accumulated. With the use of FAIMS
however, the ion mobility is able to select for a specific species at a given CV, which allows
for only selected, multiply charged RNA ions to pass through and be accumulated. Given
our first successful test of the FAIMS system with RNA, we set about next testing the
isolation of RNA modifications.
As previously mentioned, a growing field in the study of transcriptomics is
developing new methods for quantifying RNA modifications. Our goal was to select for
isobaric modifications on RNA and nucleosides to discern isobaric species, such as m6A
or m1A. We started with individual standards of adenosine, guanosine, cytosine and uracil.
RNA analysis with ion mobility has shown that the charge, cross sectional area and charge
density can play a role in the selection of analytes (51,136). The purines and pyrimidines
grouped into their respective categories due to their structure and were unfortunately too
distinct to be grouped into a single CV range for easier selection of all
nucleosides.

Another noticeable difference is the lower CV values of -10V to -20V in comparison to the
higher ones needed to properly isolate larger RNA fragments within the ~50V. We
speculated that the increased compensation voltage required for isolation is due to the
higher charger states and larger sizes, but more work must be done to determine the
relationship between charge and CV. While we could separate out the nucleosides into
distinct CV bins, the main goal was to distinguish between isobaric modifications. We first
started with using m1A and m6A mixed at 1:1 ratio to test the separation of nucleoside
isomers. First, we CV ramped the m1A and m6A standards separately and identified that
m1A and m6A had CVs of -14 and -17 respectively (Supplemental Figure 3.2). Using an
MS3 method to break down the bases to identify diagnostic ions, we then fragmented the
mixture at each CV and were able to identify the m1A and m6A diagnostic ions using
previously published spectra (145). Given the size/positions of the methylations, they
could act as a driving force for the differences in the CV values, but we next tested
modifications on a far larger molecule.
To test the selection of a modified over the unmodified RNA species, we used a
2’-o-methyl modified and unmodified Let7a to further characterize the nature of FAIMS
RNA selection. Given that the 2’-o-methylation is not dominating feature on a 22nucleotide oligonucleotide, we hypothesized there would not be enough change crosssectional area to create a difference in CV (Supplemental Figure 3.2 A and B). To our
surprise, however, we selected the modified and unmodified species on either side of the
CV ramping validated by the presence of a 2’-o-methyl uracil fragment (Supplemental
Figure 3.2 C and D). Within the same CV ramping this difference does not create two
distinctly isolate peaks, modified nucleoside diagnostic ion (Um) was found on lowest CV
and lost on the highest CV. We speculated RNA being a flexible biomolecule is able to

contain several different confirmation states while not being modified due to cis
interactions during ionization not present with the modification. The modification may limit
the number of confirmation states present and therefore limit the cross-sectional area,
creating a difference in selection CV. Overall, we are able to discern the difference
between modifications on both nucleoside and full-length RNA species and utilize this
optimization to a wider usage of this method.
While a singly modified microRNA can illustrate the basics of understanding RNA
FAIMS, a more complex sample is then required to further develop our method design.
Our next goal was to use FAIMS to site specifically localize post transcriptional
modifications on highly modified tRNA using a short 2-minute run. To set the baseline for
much of our work we decided to use E. coli tRNA due to it being previous mapped and
easily accessible. Using the previous work as a guide and a test run to identify populations
of RNA, we selected CVs from 30-70 to cover the majority of multiply charged RNase T1
digested E. coli tRNA species (Figure 2B). As seen in the figure, we can select from
different species over the FAIMS not attached (NA), where the direct spray only targets
species of RNA below the 6-nucleotide mark, below the conventual limit where the
fragmented RNA would be unique to a tRNA sequence. As we cycle through the voltages,
we shift the isolated species from about 6 nucleotides at 70V to 25 nucleotides at 50V. A
current limitation for the length limit is the poor RNA fragmentation at higher charge states
leading to limited coverage across the entire oligonucleotide (Figure 2B). This sequencing
limitation creates a curious parabolic distributions of RNA fragments isolated when
ramping from low to high CV values. Two possible reasons for this parabolic distribution
of CVs are 1) selecting for different cross-sectional area of RNA, or 2), due to the window
of selection for the MS1, we are only able to select lower mass species at higher CVs.

While this identifies the selection of size, we next interrogated the charge selection
dependency of FAIMS.
As mentioned previously, the selection of ions by FAIMS is due to the distinct
characteristics (charge and cross-sectional area) of each species which influences the
stability within a CV value. As seen in Figure 2C without FAIMS we identify mainly [M-H]3charge states of RNA, but in ramping CVs we are able to select for a distinct distribution
of charge states per voltage. Given that the majority of species within each voltage are a
different length and are therefore a different distribution of species, this leads us to believe
that while charge state is not the sole driver of CV selection. More likely, the main drivers
of FAIMS selection are due to a combination of charge and length.
We next asked if the selectivity of FAIMS may improve our RNA sequencing at either
the spectra or number of IDs generated of tRNA. The two highest hyperscore in
FAIMS not attached (NA) spectra were chosen with the respective comparison FAIMS
spectra above (Figure 3D/E). In both figures, FAIMS provides an increase of RNA
fragments and a richer spectrum overall at their respective CVs. The more fragments
generated during fragmentation, the increased confidence of both the assignment of
sequence and localization of modification within the sequence. Thus, for creating richer
spectra creates far better identifications. To test this on the broader population of spectra,
we examined fragmentation spectra quality measured by the NASE hyperscore which was
statistically significantly improved with the introduction of FAIMS (Figure 4A) (146). The
hyperscore scoring system is designed to identify and score the number of valid fragments
within a spectrum with more fragments increasing the scoring (147). Upon inspection, the
increased signal from FAIMS increases the number of ions we can fragment, highlighting
more fragment pathways and subsequently increased coverage of the RNA species

thus increasing the spectra hyperscore. The selectivity of FAIMS both decreases fill time
to reach the AGC and thereby at maximum AGC target increases the number of ions
fragmented (Supplemental Figure 4.1A). The focused window of ions selected This
increase of higher quality IDs leads to a change in coverage for the different tRNA present
within the sample.
Moving away from individual spectra towards collected spectra and oligomer
assignment, we can create more biological context to the improvement RNA MS with
FAIMS. One means of identifying the increased improvement is by examining the
coverage of tRNA. One of the major difficulties of tRNA is the level of homology between
different tRNA. Due to this biological limitation, we expanded our search space to include
multiple missed cleavages in the intent of identifying the unique coverage of each tRNA
gene. Expanding the number of allowable missed cleavages improved the numbers of IDs
(data not shown) but one major improvement was the increased coverage of tRNA across
all samples. When comparing coverage between FAIMS and not attached, the increased
sequence coverage and decreased error bars between replicates demonstrates the
reproducible identification of RNA species between each FAIMS (Figure 4C). Regrettably,
the error bars on many genes are quite large, but this is likely due to the limitations of the
Nanomate spray unable to give consistent spray beyond two minutes. Given that the
FAIMS not attached had wider error bars, we can suspect a limitation on either the spray
chips or the ionization nozzle. Regardless of that limitation, our coverage is drastically
improved with the FAIMS where we identify several tRNA genes not identified in no FAIMS
as well.
A limitation of direct spray FAIMS-MS/MS is the limited number of identifications
overall (1802 ribooligonucleotide spectrum matches) over the two-minute run time. Limited

identifications can be detrimental to both the applied FDR and coverage tRNA species
due to the large search space. Surprisingly, the 10% FDR created an actual oligomer
spectral level FDR of 2.3%, tested by using a known false human 80S rRNA sequence
database with the

tRNA sequences. Supporting this, the majority of the sequenced

“known false” rRNA spectra reported a lower NASE hyperscore in comparison to the
sequenced tRNA spectra (Supplemental Figure 4.1B).
To expand our sequence coverage from just G limited cleavage sites, we
used RNase A digestion at U/Cs, much like utilizing chymotrypsin to increase
sequence coverage over trypsin. The distribution of RNA fragments digested by
RNase A are drastically different than those of T1 (Supplemental Figure 4.2A). The
RNase A fragments create a wide bimodal distribution of species in most of the CV values,
but not a distribution of lengths possibly due to over-digestion. For the utility of RNase
A, the increased total coverage of the digested tRNA creates a complementary
sequence coverage against the RNase T1 (Supplemental Figure 4.2B). Unfortunately,
far fewer identifications were found within the RNase A digested dataset in comparison
to T1 (Supplemental Figure 4.2C). This limited number of identifications could be due to
two possible issues: first that RNase A is still over-digesting RNA to deplete coverage
in comparison to the T1 digested sequences or the RNase A sequences are less
stable due to size or base composition. Biopolymer ionization stability has long been
studied in proteomics, where amino acid composition or peptide length limits ionization
creating gaps in otherwise perfect coverage: and a similar phenomenon may be
occurring with RNase A digested RNA. Given the majority of bases being guanosine,
uracil, or cytosine within

tRNA, it would be less likely that any one RNase was

able to over digest and deplete the possible identified sequences. The answer is far
more likely to be the stability of sequences, given the

preferential fragmentation of U/Cs before Gs and the stability of guanosines, is most likely
that the terminal G present during ionization helps to stabilize the RNA for MS. Overall we
have tested several digestion methods to overcome any obstacles for RNA MS digestion.

Discussion
In this work we have created a new method for retaining and releasing RNA and a
means to better sequence RNA by selecting different distributions of RNA species. Our
efforts have developed two new methods which are able to overlap together in forming a
new platform for RNA sequencing and modifications identification/quantitation. This work
has highlighted several new directions for RNA ion mobility MS. First, an ultra-fast,
reproducible ion mobility MS method to sequence and identify RNA modifications. In
developing a FAIMS method we have increased the selectivity of for RNA and generate
far more rich and intense spectra improving the quality of data. Each separating CV
provides a window to RNA species unable to be identified without. This illustrates the true
power of the FAIMS instrumentation, where our samples are sequenced and separated at
a high rate of speed, with increased accuracy and depth of coverage. Our work stands to
improve upon the already impressive work of the original ion mobility designs for the RNA
MS work.
One major limitation of the current RNA MS field is the use of ion pairing for the
retention of RNA to C18 columns, which can limit the sensitivity of the instrument through
increased “ion burn”. To address the need of a new gradient system, we developed a PGC
based trap column to retain and release RNA followed by the separation of RNA by size
and charge. This gradient design differs from capillary electrophoresis (CE) as instead of
the analyte being selected through its own polar properties with the stationary phase
(PGC), modified under changing voltage, and releases of RNA (148). This work builds

concentration of 200ng/uL. The ionization spray voltage was kept steady at 2.2 kV in
negative mode and with the FAIMS attached we had no gas flow and user settings for the
inner and outer electrode of 70/70 oC. The compensation voltages used in the direct
injected experiments were 30, 40, 50, 60, 70V. The RF on the Thermo Fusion instrument
was set to 50% with the MS1 maximum injection time (MIT) was set to 100ms and an AGC
target of “Standard” for both the FAIMS attached and Not Attached (NA). Species were
chosen for MS2 by being greater than a charge state of 3 and a minimum intensity of 1E5.
The MS2 spectra was acquired using a 200% AGC target and a 300ms MIT. The RNA
nucleoside standards were ordered from Sigma and using the same instrument methods
as above except in positive mode.
The acquired data was processed using the OPEN MS platform and the NASE sequencing
software (146,149). The SGolay Noise Filter and Baseline filter modules were used to
better optimize our data processing before the use of NASE. Our settings for NASE were
10ppm MS1 and 10ppm MS2, similar to peptides settings, salt adducts of Na(+), K(+), and
Mg(2+) were used, and all possible RNA fragment ions (a,b,c,d and w,x,y,z). The use of
the a-Base fragment ion was used to better resolve the base and 2-o-methyl modification
when the spectra contained sufficient ion populations. Given the limited number of spectra,
an FDR of 1% was used with a score cut off. The minimum size of the RNA was at 5
nucleotides with a maximum of 25 and a missed cleavage at 3 for RNase T1 or RNase A.
Figures were rendered using RStudio and the usable scripts have been posted to the
GitHub. All statistical tests were performed using a Student’s TTest with the assumption
of normality.

The PGC electroelution used a Thermo Easy 1000 nano LC with mobile phase
A consisting of 5mM ammonium formate at pH 5 and mobile phase B consisting of
30% acetonitrile, 30% methanol and 5mM ammonium formate at pH 5. The voltages
applied to the trap column were generated from a Vol Teq voltage instrument with a
programmed gradient applied in a stepwise increase throughout the run, increasing
with the linear gradient of mobile phase B. The MS method was the same as above
with the FAIMS cycling through the same 4 CV values throughout the 90-minute total
gradient time.

A

B

Figure 1. Binary Polarity Switching on a PGC Column. A) Binary switch and release of human rRNA
from a column. Intensity denoted as from low (white) to high (black) B) Let with rRNA mixture with the
Let7 microRNA species identified in green with the abundance as a color. Intensity denoted as from low
(white) to high (black).
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Viruses require the hijacking of host cellular functions for viral replication and
progeny production and the case of adenovirus, splicing machinery manipulation being a
key part of host manipulation. Previous work has identified the manipulation of individual
host proteins and PTMs by adenovirus, but we have yet to identify the changing RNA and
protein landscape on a global proteome scale during viral infection. To this end, we have
used RBRID to identify RPI changes on a domain level during infection to understand how
RNA binding proteins are manipulated during viral infection. Through this work we have
identified decreasing arginine methylation specifically on RBPs during infection, with
protein arginine methyl transferase 1 (PRMT1), having decreased interaction with host
proteins during late infection. This is correlated with a relocalization of PRMT1 during
infection and localization associated with viral protein L4-100KDa. These findings taken
together illustrate a new pathway of regulation for adenovirus during infection and illustrate
how PRMT1 regulate RNA interaction on the domain level.

Viruses require the manipulation of host molecular machinery to replicate, create
progeny and continue the viral lytic cycle. A clear example is found within the double
stranded DNA virus, adenovirus, where ad proteins E1B-55K and E4ORF6 recruit the E3
ubiquitin ligase to degrade host DNA damage response protein MRE11 of the MRN
complex

(MRE11,

RAD50

and

NBS1)

sensors
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to

evade

host

DNA

virus

(106,110,150,151). In the transition from early to late infection, adenovirus drastically
changes transcript expression to diverse and complex late protein transcripts using
alternative splicing and polyadenylation (116). To protect this splicing switch, the virus
adapts the E3 ubiquitin ligase complex to non-degradatively ubiquitinate hnRNPC and
remove the host protein from viral splicing (126). Early work on Ad splicing discovered
recruitment of the phosphatase PP2A by E4ORF4 to SRSF1 which leads to
hypomethylation, thereby reducing SRSF1’s ability to promote early exon definition in late
infection (119,120,122). While both examples illustrate how adenovirus manipulates
cellular PTMs, these illustrate PTMs are required to regulate RNA-protein interactions.
Currently, we have yet to understand how common PTMs, such as phosphorylation,
methylation, and acetylation, change in abundance over the course of adenovirus
infection, their involvement in viral splicing, and how cellular regulation changes due to
viral factors.
Arginine methylation has been increasingly studied in recently years due to
improvements in proteomics LC-MS/MS methods and an increased focus on the function
of arginine methylation. Originally, arginine methylation was thought to be a regulatory
PTM crucial for nuclear localization of RNA binding proteins (RBPs) due to many RBPs
containing arginine motifs, methylated in high stoichiometry (152,153). Arginine
methylation is deposited by 9 different Protein Arginine Methyltransferases (PRMTs)
which are split into three classes: Type I PRMTs which deposit asymmetric methylation
(ADMA), Type II which deposit symmetric methylation (SDMA) and Type III which only
deposit monomethyl methylation (MMA) (152,153). Asymmetric arginine methylation
(ADMA) has been uncovered to play a diverse set of roles in the cell: regulation of RNA
and protein interactions, cell cycle, and DNA damage response and interferon response
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(152–158). Nearly 65% percent of nuclear ADMA is found on RBPs, and the regulation of
this mark stems from two points: the regulation of protein-protein interactions (typically
through the IDRs) or the direction RNA interactions (159,160). While classically not as well
studied as ADMA, SDMA plays a regulatory role in the immune response and more
crucially alternative splicing (161,162). Inhibition of the SDMA depositor PRMT5, a type II
PRMT, leads to splicing dysfunction caused by the hypomethylation of splicing factor
SRSF1 and thereby, its loss of splicing regulation function (162,163). Curiously, many
arginine rich domains are regulated by several PRMTs simultaneously. The arginine
glycine glycine (RGG) motif of hnRNPA1 is reported to be regulated by type I,II, and III
PRMTs, while the N-term and C-term RGGs of SFPQ are regulated by both type I and II.
While still not understood, PRMT methylation cross talk between their respective
substrates may play a role in regulating RNA biogenesis and alternative splicing (164–
168).
Arginine methylation of viral proteins is an understudied form of regulation on the
RNA and viral protein interactions during viral infection. Early work illustrated that these
methylated viral proteins were RNA binding proteins, such as adenovirus protein L4-100K
or herpes simplex virus splicing protein ICP27, and even recent work documenting SARS
Covid protein N as an arginine methylated RBP (169–173). While these are known RBPs
the field has yet to demonstrate direct RNA-protein interactions (RPI) regulated by arginine
methylation for viral or any protein

. In this work we seek to answer that gap of

knowledge with the use of proteomics to identify sites of RNA interaction and the sites of
arginine methylation for both host and viral proteins. Beyond this we seek to functionally
understand the role of arginine methylation on both the virus and host proteins and the
consequence of lost arginine methylation on both sets of proteins. Collectively this work
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identifies the overlap of RNA-protein interactions and arginine methylation changes of both
host and viral proteins during adenovirus infection and will provide new insights into the
functional roles of both.

Post translational modifications (PTMs) during adenovirus infection have been
shown to be manipulated in a limited single protein basis and currently there is no global
proteome PTM analysis during adenovirus infection. Given our overarching goal to
understand how RBPs and PTMs change in regulation during infection, we performed
fractionated proteome LC-MS/MS to gain sufficient proteome and PTM depth. Using
infected biological quadruplicate A549 cells at mock, 16, 24, 48 hpi were fractionated to
sufficient depth to identify changing PTMs (acetylation, phosphorylation, methylation)
during adenovirus infection. In total we identified over 3000 site-localized PTMs (filtered
by a PTM-RS score of 97% confidence or above). Specifically, we identified over 1000
arginine methylation sites (combining single methylation and dimethylation) which is within
range of the previous peptide fractionated datasets (Figure 1A) (162,163). Statically
significant (Students T-test p value < 0.05) changes during the time course (16 hpi, 24 hpi
and, 48 hpi) occurring in all four biological replicates were filtered from the PTMs identified.
Of the statistically significant changes during infection, we identified that arginine
dimethylation had the greatest decrease overall (~45% at 48 hpi) of the identified PTM
types (Figure 1B and Figure 1C). To further our understanding of this we focused on host
several host RBPs with the greatest decrease of arginine methylation.
We next focused on well characterized host splicing RBPs to further develop our
understanding of arginine methylation loss during infection. We first focused on hnRNPA1,
which has been previously shown to have multiple PRMTs regulating the RGG motif, and
53

found a methylation decrease at 16 and 24 hpi by greater than fourfold and are statistically
significant (Supplemental Figure S1B/C) (168). Both the R194me2 and R225me2 sites of
hnRNPA1 are single site modifications within the RGG motif decrease dramatically during
infection and are deposited by PRMT1, a type 1 PRMT (Supplemental Figure 1A and
Supplemental Figure 1C) (164,168,174). With this we interpreted decrease of PRMT1
deposited sites during infection. Validation of proteome wide methylation loss can be seen
using antibodies specific for ADMA, SDMA and MMA during infection (Supplemental
Figure 1E). To understand further about arginine methylation changes during infection we
next asked if viral proteins also retain arginine methylation.
Viral

proteins

during

infection

unsurprisingly

contain

post

translational

modifications which increase in abundance throughout infection. Two notable proteins
stand out as major accumulators of PTMs: DBP for serine phosphorylation and L4-100K
for arginine methylation both validated by previous literature (Figure 2A and Figure 2B)
(171,175–178). Furthermore, the MMA infection time course western contains a large
band forming above 100 kDa, likely L4-100K, also seen in previously published work to
be asymmetrically methylated and assumed to be monomethylated due to its
dimethylation status (Supplemental Figure 1E) (175). While the modifications do not
increase in unique sites during the course of infection, the abundance of these sites do
change over the course of infection (Figure 2C and Figure 2D). The temporal nature of
viral proteins not only applies to their expression, but also their function during infection
and a convenient means of regulating the functions of proteins is by region specific PTMs.
Curiously on viral protein L4-100K there is a cluster of PTMs found within the C-term of
the protein both within and near the RGG motif. This region may be under strict regulation
and due to L4-100K roles during infection (including viral RNA binding) and the
PTM
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abundance could regulate a shift in function. To grasp a better picture of the changes on
both host and viral RBPs during infection, we sought to map changing PTMs with changing
RNA and protein interactions.
To further examine the changes on host RNA binding proteins during infection we
asked if global RNA-protein interactions were changing over the course of infection. To
answer this, we used proteome wide SILAC RBRID to examine how RPI may change
during the course of a DNA virus infection (92). Our experiment was designed taking into
account the changing PTM landscape between early and late phase infection and we took
a time course of 0hpi (Mock), 16 hpi (Early) and 24 hpi (Late) in SILAC biological triplicate
HeLa cells (Figure 3A). To improve upon the technique at the proteome wide level, we
incorporated SILAC labeling and peptide level fractionation to increase the peptide level
coverage (179). The SILAC peptide pairs per experiment were found to be in equal
distribution and individual peptide log transformed heavy/light abundance distribution
aligned to 0 indicating even abundance between both heavy and light channels
(Supplemental Figure 3A and 3B). As well, the heavy/light ratios are found to be highly
correlated between each of the timepoints and their respective replicates (Supplemental
Figure 3C). In total we identified 2,500 dropout peptides of 100,000 peptides present,
which mapped to ~1200 proteins containing dropout peptides. To qualify our total dataset,
we compared our identifications against 3 recently published methods for RPI
identifications in human HeLa cell lines: XRNAX, OOPS and CAPRI (90,91,180). While
we did not identify more proteins than XRNAX, our data was in 80% agreement with the
previous datasets at the protein level, creating confidence in our dataset (Supplemental
Figure 3D). We next examined the domain and functional enrichment of the proteins
identified by GO enrichment analysis and discovered this dataset was enriched in both
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RBP protein functions and RNA binding domains: the three most enriched domains
(“Nucleotide biding”, “RRM” or “P-loop” domains) all commonly found on RNA binding
proteins (Supplemental Figure 3.2A).
To view the temporal nature of RPI during the course of infection, we mapped out
changing RNA interactors over the course of infection (Mock, Early and Late) and grouped
proteins by RPI changes. At the protein level we found the majority of proteins continue to
interact with RNA throughout infection, followed by those which gained RNA interaction in
late phase (Figure 3B). From a practical perspective, it is unsurprising RNA binding
proteins would not drastically lose RNA interaction during early infection, as the virus still
requires the cellular proteins to continue the majority of cellular functions. From our
perspective the more interesting proteins are those “lost in late” and those “gained in late”:
proteins which are gaining or losing RNA interaction during infection. We surmised from
these two layers of data that while the majority of proteins continue to interact with RNA,
this is not the case at the domain or even peptide level. This difference is clearer at the
peptide level, seen in Figure 3C, where RNA interaction changes over the course of
infection are more evenly distributed changes without any form of enrichment in any one
group. We interpreted this to mean that while proteins remain as RNA binders, their
domains, and thereby their functions could change during infection. Domain level proteinRNA interactions diverge in interaction change during infection, KH domains and P-Loop
(commonly found in RNA helicase domains) are more likely (as determined by a Fisher
Exact Test) to change RNA interaction during infection while RRMs remain constant
throughout infection (Figure 3D). Example peptides within domains as peptides illustrating
these changes occurring over the course of infection (Figure 3E-H). These individual
peptides within RNA binding domains illustrate how not only RBRID can track RPI
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changes at a peptide level, but also how specific protein domains and regions change
throughout infection. Taken together this illustrates a change at the domain level during
infection, either by changes in regulation or by cellular changes during infection.
Previously in this work we had identified loss of arginine methylation of RBPs
during infection and to expand on this, we examined methylated proteins with changing
RPI. By plotting the comparison of heavy to light abundances of known methylated splicing
factor proteins, SFPQ and hnRNPA1, over the course of infection we found divergent RNA
interactions. The SFPQ R7/9me2 dropout peptide gains interaction late in infection, the
interpretation being loss of arginine methylation correlates to a gain of RPI (Figure 4G).
Opposing this however, hnRNPA1 R225me2 (within the RGG motif) loses RPI with the
decrease of methylation (Figure 4H). Taken together these results illustrate divergent
changes during infection with the loss of arginine methylation and the possibility targeted
change either to the methyltransferase or to the proteins being modified. Given that both
of these proteins are regulated by PRMT1, this would be a high confidence candidate
follow up for changing regulation during infection (181). Like cellular proteins, adenovirus
viral proteins can also be RBPs and we have used RBRID to quantify their changing RPI
throughout infection.
Just as cellular protein RPI can infer a domains function, adenovirus also
expresses viral RBPs. Using the RBRID proteome data set we also examined the RNA
and protein interacting domains of viral proteins between 16 hpi and 24 hpi (Figure 4A and
4B). At 16 hpi the major protein dropouts identified were within known viral RBP L4-33K
along with novel viral RBPs IVa2 and MLi (124,125). At 24 hpi the viral RBP L4-100K
becomes the most confident dropout, the domain found next to the RGG and GAR motifs.
Curiously, the viral proteins and regions alternate between 16 and 24 hpi, which may
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indicate a changing RNA interaction or domain regulation for viral RBPs over the course
of infection. A caveat of proteome RBRID is high protein coverage of proteins is limited to
highly abundant proteins limiting our RNA domain coverage and our understanding. For
example, viral proteins which are low in abundance at 16 hpi the proteins with sparce
coverage due to below the limit of detection peptides might be dropouts, which may
reverse at 24 hpi with increased abundance and coverage. Grouping peptides identified
in both 16 hpi and 24 hpi, we can identify the L4-100K RGG motif to be a strong RPI region
for the protein, with the most confident fold change at 24 hpi (Figure 4C/Figure 4D). In the
previous viral PTM data, L4-100K contained the highest population of PTMs (both arginine
methylation and serine phosphorylation) in the region which contained the highest
confidence dropout peptides. We sought next to investigate both the loss of ADMA on host
RBPs and the relevance of ADMA on L4-100K by understanding the regulation of PRMT1
during infection.
To understand the role of PRMT1 during adenovirus infection we first performed
IP-MS to identify changing host and viral interactors during Mock and 24 hpi as outlined
in Figure 5A. The comparison of host proteins between Mock and 24 hpi visualized a
striking loss of host RBPs interaction at 24 hpi (Figure 5B). This trend was found to be
statistically significant for nearly 200 proteins, with RBPs losing interaction with PRMT1
(Supplemental Figure 5C). Beyond those two, we also identify major decreases of
interaction with double stranded RBPs STAU1, ILF3, and ADAR: of which ILF3 was found
to have a modest loss of arginine methylation at 24 hpi. With a dramatic loss of host
interactors at 24 hpi, we hypothesized viral interactors which might be instigating this
change. We compared to our 24 hpi infection to a rabbit IGG serotype control and
identified several statistically enriched viral interactors of PRMT1, notably L4-100K, UXP
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and E1B-55K (Figure 5C). Previous work has identified PRMT1 as a modifier of L4-100K,
but this experiment has identified the viral protein as one of the most prominent interactors
during infection (Supplemental Figure 5A and 5B). Taken together, these results suggest
PRMT1 loses interaction with cellular proteins, while viral protein L4-100K becomes a
major interactor of PRMT1.
With L4-100K being the chief interactor during infection, we hypothesized the viral
RBP’s interaction with PRMT1 results change in either PRMT1’s localization or ability to
methylate host RBPs. To our surprise, PRMT1 exports to the cytoplasm over the course
of infection (Figure 5D), coinciding with the loss of nuclear ADMA (Figure 5E), and
agreeing with the decreased interaction in the IP-MS dataset (Supplemental Figure 5C).
During the same timepoints, immunoblotting revealed a decrease ADMA starting at 16 hpi
within nuclear fractionated samples through 24 hpi (Figure 5F). Overall, these results
illustrate a manipulation of PRMT1 for the benefit of L4-100K resulting in a loss of ADMA,
the consequence of which we will further understand by following hnRNPA1.
The previous proteome RBRID, PTM and PRMT1 IP-MS datasets illustrated a loss
of arginine methylation and RNA interaction coinciding with a decreased interaction
with PRMT1 during infection. Given hnRNPA1’s critical role in splicing and previous
pro-viral roles in other viruses, we focused on hnRNPA1’s role during adenovirus
infection (182–184). To assess if hnRNPA1 is required for adenovirus infection, we
knocked down hnRNPA1 using siRNA in A549 cells and immunoblotted for viral early
and late proteins (Figure 6A). We identified a decrease of late proteins Hexon and
Penton during 16 hpi and 24 hpi with no major effects on GAPDH. Subtly, we identified
the loss of isoforms of E1A, which collapse into a single species with knockdown of
hnRNPA1. We interpreted this as hnRNPA1 has a role during adenovirus infection
as a splicing protein of viral
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transcripts due to changes of E1A isoforms and loss of late proteins. To further speculate
at the role of hnRNPA1 during infection, we used immunofluorescence to localize
hnRNPA1 over the course of infection. As we expected, hnRNPA1 localized around viral
replication patterns (demarked by USP7) thought to be sites of viral splicing (Figure 6B).
From mock to 16 hpi, we visualized relocalization from a diffuse pattern to one localizing
directly around viral replication centers, in a circle pattern similar to that of other splicing
proteins such as hnRNPC (129). By 24 hpi hnRNPA1 has distorted from the ring shapes
to a more webbing like shape throughout the nucleus, which coincides with the loss of
arginine methylation of R194me2 and R225me2 during infection. Therefore, hnRNPA1 is
pro-viral and necessary for efficient expression of viral proteins, and given the localization
of hnRNPA1 during infection, we suspect it has a role in viral splicing.
To understand whether the loss of arginine methylation affects hnRNPA1 RNAprotein interactions we performed targeted RBRID. We enriched hnRNPA1 by
immunoprecipitation in SILAC RBRID HeLa cells at mock and 24 hpi to match the loss of
arginine methylation from our PTM dataset (185). By enriching hnRNPA1 and using
chymotrypsin in addition to trypsin, we were able to increase our coverage from 30%
proteome sequence coverage to 85% sequence coverage, however, the intrinsically
disordered region lacks sufficient coverage due to too small of peptides generated by both
trypsin and chymotrypsin. Overall, there are surprising losses of RNA and protein
interaction within the RGG of the protein (R194-R225) (Figure 6C). In mock, the hnRNPA1
RGG contains modified peptides interacting with RNA, but during 24 hpi, the same
peptides have reduced RNA interaction. The second RRM, known to be the main
requirement of hnRNPA1 splicing function, contains dropout peptides in both mock and
24 hpi: suggesting hnRNPA1 retains some splicing function during infection (169,186–
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188). Overall, this provides an interesting observation of how arginine methylation
mediates the interaction of between RNA and proteins and adenoviral mediated loss of
interaction regulation.

In this work we have identified changing RPIs during adenovirus infection, and in
doing so have identified a global loss of arginine methylation on host proteins and the gain
on viral RBPs. As well, arginine methylation is reported to be required for L4-100K nuclear
localization, but our work has shown methylated RGG interact with RNA predominantly at
24 hpi. Infection draws away PRMT1 from its typical nuclear localization and even change
the distribution of ADMA during infection (174,178,189). The loss of arginine methylation
creates a change in RPI within the RGG of hnRNPA1 leading to a loss of RNA interaction
within the region, while other regions of the protein remain interacting. The identified loss
of arginine methylation coincides with a loss of RNA interaction in hnRNPA1, a surprising
consequence since methylation is thought to “block” the sites of interaction between either
protein or RNA (163,190). Thus, we can identify how arginine methylation can be
manipulated by adenovirus through the relocalization of PRMT1 away from nuclear RBPs.
This work is the beginning of several avenues of research focusing on the
regulation of RNA binding domains by PTMs. More specifically, we can begin to map the
regulation and crosstalk of different PRMTs arginine methylation sites within a single RGG
and the motif’s broader regulation of RNA binding proteins. While the methylation sites
outlined in this work are mainly under PRMT1 regulation, further study how other PRMTs
regulate RNA binding of host and viral proteins. Multiple methylation types or the
regulation of several PRMTs on the same regions could be acting as a “RBP code” in
regulating the specific protein and RNA interactions. Given that RBPs are highly modified
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proteins, it stands to reason that the high rate of modifications is to modulate the RNA
binding of proteins: both host and viral. In this we have uncovered a possible new pathway
in arginine methylation and the possible consequence of PRMT1 manipulation on host
RBPs. In the nearly 50 years of studying adenovirus, we are still uncovering new pathways
this virus manipulates and controls host cells for the benefit of the virus.

The proteome viral RBRID work was performed in HeLa cells and passaged six
times to ensure sufficient labeling with the R10 and K8 heavy arginine and lysine
respectively grown in DMEM SILAC media. We checked label incorporation using a basic
1-hour proteome LC-MS/MS run which showed sufficient (>99.9%) labeling. The
timepoints were each staggered into triplicates in 10cm2 and infected with WT Ad5 at an
MOI of 10 for 16hpi and 24hpi in serum depleted media and rocked for 2 hours before
replenishing media. Two hours before harvesting 0.5 mM of 4-thiouracil was added to the
media of the heavy cells. The staggered cells were washed twice with ice cold media and
kept on ice before irradiation with 312nm light a 1J/cm2 using a SpectralinkerTM UV
crosslinker. The cells were scraped and heavy and light pairs were collected and
combined at the cellular level and frozen at -80C.
The cells were then lysed with 8M urea and sonicated in a Diagenode BiorupterTM
bath sonicator at 4C on high 30 seconds on and 30 seconds off for 5 minutes. The cells
were centrifuged at 10,000xg for 10 minutes at 4oC and the lysates transferred to a new
tube. The lysate was then reduced with 5mM dithiothreitol (DTT) for 1 hour at RT and
alkylated using 10mM iodoacetamide (IAM) for 45 minutes in the dark and 15 minutes in
the light, followed by trypsin at a 1:50 ratio overnight at RT.
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The following day 200ug of peptides for each timepoint and bio-replicate was high
pH fractionated using Hamilton spin tip columns into eight fractions containing equal
peptides per fraction in increasing hydrophobicity. Samples were then reconstituted in
non-overlapping fractions, then desalted using homemade stage tips. Samples were run
on a standard linear 2-hour gradient using standard proteomics buffers of 0.1% formic
acid in aqueous and 0.1% formic acid in 80% acetonitrile (ACN). Samples were quantified
using a Thermo FusionTM MS instrument and batch randomized to account for instrument
variation. The DDA MS method was designed with the MS1 having a window of 3301100m/z, AGC target of 1E6 and MIT of 75ms with the MS2 having automatic windows,
AGC target of 200% and MIT of 120ms to account for higher charge state species. The
selection for ions were charges 2-8, minimum peak intensity of 1e4, and a 3 second
maximum cycle time.
Data files were processed using Proteome Discoverer 2.4 in a cascade style
processing path to limit the FDR penalty for the increased search space. Files were first
processed in Seaquest using Uniprot human and canonical Ad5 fasta for protein
identifications and then hits that were not “high” in confidence were sent to Byonic to
sequence. Sequest settings were 10ppm for precursor and 0.02Da for fragment thresholds
for peak assignment. In byonic processing phosphorylation and methylation were set as
variable modifications with 4 missed cleaves. The FDR for both was set to 1% for PSM
identifications. The PTM were filtered for site specific localization of 90% or higher by
PTMRS. Peptides that passed these filters were then again filtered with a 1% FDR for
peptide and protein assignments. Data was then further processed in R, filtering for heavy
and light pairs found in all timepoints, normalizing by medians for heavy and light
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proteomes. A two-sided Students T-test in each condition comparing heavy to light
conditions to determine dropouts in each condition.

The post translational modifications were identified through using the previously
published fractionated whole cell data published in Dybas et al (191). In PD2.4 we used a
cascade approach using first Sequest and Byonic for adenovirus peptides and modified
peptides respectively followed by cellular Sequest and Byonic peptides and modified
peptides with a 1% FDR for each. Modified peptides were filtered for a PTMRS score of
90% or higher. An ANOVA was used using mock as the reference requiring to be present
in all four bio replicates, present in mock-24hpi and statistical significance was limited to
a fold change of 0.5 and a p.value less than 0.05. Data post-processing and figures were
created in R and adjusted in Adobe Illustrator.

Cells were lysed using 1x lithium dodecyl sulfate (LDS) supplemented with 10mM
DTT and boiled at 95oC for 10minutes. Westerns were performed on 12% SDS PAGE gels
for all PTM westerns and 4-12% for all protein westerns. Westerns were transferred to
PVDF for 8 hours at 30V and blocked in 5% milk in Tris-buffered saline with Tween-20
(TBST) for one hour and incubated in primary overnight. The PVDF was washed with
TBST 3 times in 30minutes and secondary added for one hour. Blots were developed
using ECL and visualized using a Gbox.
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A549 cells were grown in F12 media infected with WT Ad5, washed with cold PBS,
scraped and spun down at 4000 x g. Cells were lysed in 20mM Tris pH 7.4 at 4C, 150mM
NaCl, 1% NP-40 and HALT inhibitors. The cells incubated on ice for 10minutes in lysis
buffer then sonicated using a Diagenode biorupterTM on medium for 30 seconds on and
30 seconds off for 5 minutes. Lysates were spun at 10,000xg and measured for
concentration by BCA and normalized to 1ug/ul per condition. Samples were rotated at
4C overnight with 5ug of antibody (PRMT: ab73246, hnRNPA1:4B10 NB100-672) added
to each. Next morning, 35uL of protein G coupled beads washed three times with lysis
buffer and added and rotated for 3 hours at 4C. Beads were extracted using a magnet set,
washed three times with lysis buffer and settled in ice. Cells were then washed six times
with wash buffer (20mM Tris pH 7.4 at RT, 137mM NaCl) and then rested on ice. Bound
protein was eluted either with 40uL 0.2 M Glycine at pH3 if proceeding to MS or 1x LDS
with 10mM DTT if proceeding to western. Samples prepped for MS used the same protocol
as the proteome samples and samples for western we treated as protein or PTM samples
as outlined in Westerns.

A549 or HEK293A cells were grown in 24-well plates, infected or transfected where
indicated and fixed with 4% paraformaldehyde in Phosphate Buffered Saline (PBS) for 10
minutes. Cells were permeabilized with 0.5% Triton-X in PBS for 10 minutes. Samples
were then blocked in 3% BSA in PBS for 30 minutes and incubated with primary antibodies
(PRMT: ab73246 dil:1:1000, hnRNPA1:4B10 NB100-672 dil:1:1000,USP7:A300-033A
dil:1:500) in 3% BSA in PBS for 1 hour followed by secondary antibodies (Alexa Fluor antirabbit 488 and anti-mouse 555) and 4,6-diamidino-2-pheylindole (DAPI) for 2 hours.
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Coverslips were mounted using ProLong Gold Antifade Reagent. Coverslips were
visualized using a Zeiss LSM 710 Confocal microscope and ZEN 2011 software.

HEK293A cells were grown to 50% confluency in 12 well plates, then transfected
with 1ug TPL-L4-100K plasmid and Lipofectamine 2000. Cells were grown for 24 hours
post transfected and either lysed for westerns or mounted for microscopy. A549 cells were
grown to 60% confluency and using Lipofectamine with 3ug of hnRNPA1 siRNA and
incubated were transfected and grown for 24 hours. Cells were infected at a MOI of 10
and lysed for western blot analysis.
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Figure 1. Decrease of Cellular Arginine Methylation During Adenovirus Infection. A) Model of experi-mental design. B)
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In this work we have designed two new methods to improve the sequencing of
RNA by LC-MS/MS, yet more improvements on the method are necessary for the greater
expansion of the RNA MS platform. Two major limitations of RNA MS are the inability to
read longer sequences and the inability to sequence over the entire transcriptome. This is
due to ionization and fragmentation having a maximum sequencing length of around 100
nucleotides. This limit is perfectly fine for small non coding RNA species and tRNA, but
MS based sequencing would be unable to localize fragments of long repetitive sequences
such as a full-length rRNA or complex mRNA, requiring improved fragmentation and
mapping. Both effective fragmentation and improved sequencing are intertwined as
increasing fragments in intensity and diversity creates more data for the program to utilize.
Using UVPD or AI-NETD would improve fragmentation for longer species of RNA (greater
than 50nts) and will drastically improve the coverage we can ascertain on longer species
of RNA, such as cleaved mRNA or lncRNA (66). With these improvements we can identify
unique sequences which will be mapped back to the original mRNA/lncRNA transcript with
far more confidence than any sequence of only 20-30nts in length.
Beyond fragmentation, RNA length can also be a limitation for the search space
size due to the use of proteomics styled decoy-based sequencing. With decoy database
searching there is a limit in theoretical size. As the search space of our data grows, the
more penalizing the 1% FDR becomes and the increased likelihood random decoy
sequences can match (192). With the addition of 20-30 modifications, as is in our tRNA
datasets, the search space increases to a size that limits our IDs. To surpass these
limitations, we must remove the hyperscore style approach with the implementation of a
MASCOT styled scoring system for longer sequences (78). Overall, with these two
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improvements we can create a massive impact on the ability to sequence RNA and to
identify RNA modifications within transcripts.
While we have outlined improvements to MS instrumentation and computation, we
can improve upon the EMLC method to further optimize RNA elution. The current
limitations with this method are 1) the lack of uniform graphite creating disruptions in trap
column packing and 2) limited trap column conductivity and applied voltage creating
limited separation. For the first limitation, our current system uses PGC extracted from
HPLC trap columns designed for high flow (1mL/min) systems not designed for nanoflow
chromatography. The rough and irregular structure of the PGC coupled with the nonstandard size graphite sheets creates uneven packing on trap columns, leading to
eventual clogging with repeated injections of RNA. To circumvent this, we propose to
either decrease the size of graphite down to 1-2 micron or create a monolayer design for
the graphite, akin to a nanotube, which is designed similar to commercial C18 monolith
columns (193,194). Two major advantages of the monolith design are a decreased
probability of clogging and an evenly applied voltage throughout the nanotube. One
current obstacle of achieving this is determining the theoretical plate limit for RNA using
the voltage gradient, as it is currently unclear if we have reached capacity of RNA binding
during loading. For the future we must examine the limits of binding for RNA and the use
of monolith columns to compare the analytical capabilities of each.
Another major limitation of this method is the limited resolution in retention time for
each analyte for the trap column leading to peak broadening. Separately from improving
the PGC size and shape, improving voltage application and conductivity, could
mitigate this issue. Our current design places the voltage clips on metal unions on the
outside of trap column, but given that the lines are silica and the connectors are
plastic limits the
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applied voltage applied and can interfere with ionization. To circumvent this issue, we can
apply a metal junction cap frit on either side of the trap column minimizing the loss of
voltage through lead contact by direct contact. Overall, with these changes we can vastly
improve the system at hand and drastically increase our selectivity and open the method
to identify beyond just RNA modifications.

Protein-RNA interactions are a fundamental part of RNA biogenesis, regulation of
transcripts and fundamental biology. To uncover new discoveries, we must develop new
methods to address the questions being asked of this expanding field. While several
groups have identified the interactors of viral mRNA, in this work we have mapped
temporally changing interactors during infection (195). These findings create a curious
question for RBP function: what is the dominance of each RNA interacting domain and
how do the individual RNA interacting domain functions play contribute to protein function.
In our future directions we seek to improve upon the methods outlined in this document
and the contribution of different RNA binding domains during adenovirus infection.
One major limitation is the depth of peptide (and therefore domain) coverage we
can reach using both a fractionated SILAC combined with DDA analysis. In a recently
published paper, we utilized 4m/z windows SILAC DIA to bin peptides and quantify both
channels of heavy and light without MS1 level peak matching and integration (196). The
LOD and dynamic range using DIA far outperformed the DDA based method design which
can be easily adapted in our efforts to improve RBRID. DIA would limit the mis-quantitation
of peptides while also increasing the dynamic range of quantifiable peptides, increasing
our depth of coverage and increasing confidence in identified dropouts. However, this path
only continues the direction for better identifying “dropout” peptides while the community
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is moving towards the use of positive ID, the identification of the crosslinked nucleotide,
for RNA interaction mapping.
Positive ID for RNA-protein interaction mapping contains its own limitations, chiefly
being the charge distribution, size and gas phase stability of crosslinked peptide-RNA
species. Lack of specialized methods for recovery and identification may limit positive IDs
in comparison to the more common negative ID mapping (RBDMap or RBRID). The length
of crosslinked RNA post trypsin digestion would reduce C18 retention during MS clean up
due to the increased hydrophilicity. Several groups have previously used silica enrichment
to enrich RNA-peptides with surprisingly limited results (67,93). In addition to retaining
crosslinked peptides, a lack of specialized fragmentation for site specific localization and
identification of RNA crosslink site is hindering the progression to a robust positive ID
method. To design a method to sequence both the RNA and peptide simultaneously
requires designing a non-traditional type of fragmentation method and a new type of MS
computational mapping to confidently sequence both RNA and peptide. To achieve this,
we would design an MS3 method to first identify RNA crosslinked peptides by a gently
fragment the RNA (MS2) followed by selection and a stronger fragmentation to sequence
the crosslinked peptide (MS3). By fragmenting the RNA and peptide sequentially the RNA
and peptide sequences are linked in time, making assignment far easier. This MS method
design, however, would require considerable downstream pipeline work to sequence the
peptide and the RNA. Each MS2 and MS3 spectra could be separated and create a
probabilistic styled permutation of RNA and peptide sequence respectively, much like with
the previously mentioned MASCOT. As validation, we can examine the lower m/z region
and identify the presence of nucleotide bases as diagnostic ions within the MS2 and MS3
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spectra: indicating crosslinked RNA. While difficult, this technique stands to be a fruitful
option for the identification of RPI and further the field to new heights.

Viral proteins are manipulators of host proteins to create a more hospitable
environment for the viral lytic cycle through manipulation of host modifying proteins.
Through this work, we have theorized PRMT1 relocates away from host proteins due to
L4-100K creating a sink of methylation due to high expression, however, we have yet to
uncover the mechanism behind the decrease of host arginine methylation. To uncover
this, we must first understand the role L4-100K methylation (by any PRMT) within of the
context of infection and to understand if L4-100K alone can manipulate host arginine
methylation.
Arginine methylation is crucial viral protein L4-100K function during infection, but
which host modifiers methylate L4-100K and which can be “inhibited” has yet to be
uncovered. A theory placed forth by the Richard lab is PRMTs will localize to the greatest
concentration of unmethylated arginine. During late infection viral protein L4-100K is highly
expressed- thereby increase the RGG/GAR motifs present in the cytoplasm directly after
translation. To further understand the localization and possible inhibition of PRMTs during
adenovirus infection we will transfect L4-100K into cells and monitor the localization of
PRMTs 1,4,5 and 7 to clarify which PRMTs (type I, II, and III) are affected during infection.
If the high proportion of RGG/GAR expression is the driving force behind the relocalization
of PRMT1, and possibly the other PRMTs, it would thereby create the loss of methylation
on RBPs through competition. To assess this, first, we would validate that L4-100K alone
is sufficient to change the cellular location of PRMTs and decreased methylation of RBPs,
83

followed by the truncation of L4-100K RGG and GAR. The removal of the RGG domain
would specifically decrease interaction with PRMTs, validated in a co-IP, if the major
interacting region for PRMTs is within the methylated motif. Given our recent work
identifying the GAR motif is likely to be modified by SDMA, with the highest confidence
candidate protein being PRMT5 (the highest abundance type II PRMT) modifying later in
infection. To validate this, we will perform co-IP on a transfected FLAG 100K to confirm
PRMT5 interaction with 100K and loss of interaction with the GAR deletion mutant. With
the modifiers established, we can test the requirement of the RGG and GAR domains of
L4-100K and establish the link between the methylation and function of the protein.
While this work would establish which PRMTs interact with L4-100K, it does not
determine if L4-100K acts as an inhibitor towards PRMTs and the role of these domains
in RPI selectivity. To assess the arginine methylation inhibition properties of L4-100K, we
must identify if the RGG and GAR motifs separately are concentration dependent for the
inhibition of RBP methylation, acting as a competitive inhibitor for PRMTs. By utilizing
isothermal calorimetry for direct binding measurements in comparison to known host RGG
peptides and transfection and expression of the L4-100K RGG and GAR motif separately
through a concentration dependent titration of both. If the interaction with L4-100K is more
favorable, we can interpret the methylation of L4-100K as a “sponge” for arginine
methylation, redirecting away from host arginine methylation. To assess if L4-100K alone
is sufficient to promote a decrease of arginine methylation on host proteins (such as
hnRNPA1), we can transfect L4-100K, the RGG/GAR motif alone, and without the
RGG/GAR alone followed by LC-MS/MS to quantitatively identify a decrease of host
arginine methylation. These results combined will assess if the binding of L4-
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100K is greater than that of other host proteins, the expression of the RGG motifs drives
RBP loss through competition and drives relocalization of PRMTs.
As discussed in this work, arginine methylation is a crucial regulator of a myriad of
different crucial cellular functions, from splicing to DNA damage response. During
adenovirus infection we quantified a global decrease of arginine on cellular RBPs. Our key
candidate protein found in each of the data sets, hnRNPA1, is a known splicing/RNA
export associated protein with multifaceted roles. Previous work uncovered PRMT5/7
deposition of hnRNPA1 R206me2 and R218me2, sites also known to regulate of
preferential binding of hnRNPA1 to regulated transcripts. Our identification of known
PRMT1 deposited R194me2 and R225me2 decrease during infection, of which there is
no known function for these methyl sites. To further the field, we must understand how
these methylation sites directly regulate hnRNPA1 RNA-protein interactions or proteinprotein interactions.
In conclusion, our work stands to uncover two separate pathways coalescing into
the regulation of RPI and arginine methylation. These regulations are caused by
the modification of specific arginine methyltransferase and subsequently drawing away
from host protein interactions for methylation of its own viral proteins. The decrease of
arginine methylation on RBPs is an opportunity to identify arginine methylation
dependent and arginine methylation guided RNA-protein interactions. Looking forward,
we must discern the RNA interacting domain regulation by PTMs and link the
downstream response, such as alternative splicing changes or phase separation. This
then brings us to our greater goal, to map the regulation of RNA-protein interaction
through modifications, much like histones and their multi-regulatory PTMs.
PTMs governing RNA-protein interactions creates the idea of a “RNA-binding
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pecific

code”: in essence, the regulation of RNA interaction through PTM deposition by protein
modifiers. RBPs are known to be highly modified, with their RNA interaction regions being
known “hot spots” of PTM regulation. In the future, the greatest path to set upon is
identifying the regulation of post transcriptional modifications, post translational
modifications and their mediation of RNA-protein interactions.
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